Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal

Executive Summary

FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed

You may also be interested in...



BI’s Tradjenta Lesson: Don’t Try To Use CV Trial To Score Head-To-Head Efficacy Evidence

Boehringer Ingelheim GmbH saw an opportunity to gather more and better head-to-head data for anti-diabetic Tradjenta in its post-market cardiovascular outcomes trial, but FDA couldn't picture a better comparator than gold-standard placebo.

BI’s Tradjenta Lesson: Don’t Try To Use CV Trial To Score Head-To-Head Efficacy Evidence

Boehringer Ingelheim GmbH saw an opportunity to gather more and better head-to-head data for anti-diabetic Tradjenta in its post-market cardiovascular outcomes trial, but FDA couldn't picture a better comparator than gold-standard placebo.

Korea FDA Sends Precautionary Notice To Doctors For Diabetes Drugs Containing Rosiglitazone

SEOUL - South Korea's Food and Drug Administration issued its second precautionary notice to doctors, calling for caution in prescribing diabetes drugs containing rosiglitazone, including GlaxoSmithKline's Avandia and Avandaryl, Sanofi Aventis' Amavan, and local Korean Yuhan Corp.'s generic rosiglitazone

Related Content

UsernamePublicRestriction

Register

PS048402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel